Pfizer Announces New Chief Medical Officer

New York, February 24, 2025 – Pfizer Inc. (NYSE: PFE) today announced that Patrizia Cavazzoni, M.D. will rejoin the company as Chief Medical Officer, Executive Vice President. In this role, Dr. Cavazzoni will lead Pfizer’s regulatory, pharmacovigilance, safety, epidemiology, and medical information and evidence generation, among other medical functions, and will report to Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President, Pfizer Research & Development. Dr. Cavazzoni will succeed Aida Habtezion, M.D., MSc, FRCPC, AGAF who will be leaving Pfizer to pursue other opportunities.

Dr. Cavazzoni is a world-class developer of medicines across a wide range of therapeutic modalities and has more than 25 years of experience in clinical development, pharmacovigilance, clinical operations, regulatory affairs, safety risk management, pharmacovigilance, epidemiology and R&D strategy.

Dr. Cavazzoni was most recently Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration, where she ensured the availability of safe and effective medicines and led the regulatory and policy decisions on prescription and over-the-counter medicines. Under Dr. Cavazzoni’s leadership at CDER, there was significant innovation in drug evaluation and research, with a focus on advancing public health initiatives.

Before joining CDER, Dr. Cavazzoni held several senior executive positions in the pharmaceutical industry for nearly two decades, including at Pfizer, Eli Lilly, and Sanofi. During her prior tenure at Pfizer, Dr. Cavazzoni led clinical sciences and development operations for the company across multiple senior roles.

Dr. Cavazzoni received her medical degree from McGill University and completed a residency in psychiatry and a fellowship in mood disorders at the University of Ottawa, where she also received a full-time appointment to the Faculty of Medicine. While at the University of Ottawa, Dr. Cavazzoni joined the Mood Disorders Program at the Royal Ottawa Hospital with both patient and student-facing roles, and advanced research on genetic predictors of bipolar disorder. Dr. Cavazzoni is an author in numerous peer-reviewed scientific publications.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice
The information contained in this release is as of February 24, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking statements that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s product candidates; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Media Contact:
+1 (212) 733-1226
PfizerMediaRelations@Pfizer.com  

Investor Contact:    
+1 (212) 733-4848
IR@Pfizer.com